MARKET

ARAV

ARAV

Aravive Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.89
+0.10
+1.73%
Opening 11:09 08/12 EDT
OPEN
5.83
PREV CLOSE
5.79
HIGH
6.03
LOW
5.79
VOLUME
58.84K
TURNOVER
--
52 WEEK HIGH
15.62
52 WEEK LOW
3.340
MARKET CAP
94.35M
P/E (TTM)
-3.0578
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARAV stock price target is 27.75 with a high estimate of 31.00 and a low estimate of 24.00.

EPS

ARAV News

More
Aravive EPS beats by $0.14
Aravive (NASDAQ:ARAV): Q2 GAAP EPS of -$0.32 beats by $0.14. Cash and cash equivalents of $60.1M. Press Release
seekingalpha · 08/04 01:42
Aravive shares are trading lower after the company reported Q2 EPS of $(0.32), down from $(0.27) year over year.
Benzinga · 08/03 20:15
Aravive Q2 EPS $(0.32) Down From $(0.27) YoY
Aravive (NASDAQ:ARAV) reported quarterly losses of $(0.32) per share. This is a 18.52 percent decrease over losses of $(0.27) per share from the same period last year.
Benzinga · 08/03 20:09
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
* Successfully completed Phase 1b trial of AVB-500 in Platinum Resistant Ovarian Cancer with encouraging clinical data showing 60% ORR in the subpopulation that has not previously been treated with bevacizumab * On-track to discuss the potential pivotal trial
GlobeNewswire · 08/03 20:01
Aravive to Participate in Upcoming Virtual Investor Conferences in August
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following three virtual inve
GlobeNewswire · 07/30 11:00
The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22)
Benzinga · 07/23 12:25
IBIO, TNXP among premarket gainers
Seeking Alpha - Article · 07/23 12:25
Aravive Reports Successful Completion Of Phase 1b Trial Evaluating AVB-500 In Platrinum-Resistant Ovarian Cancer
Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the successful completion of the Phase 1b trial of its AVB-500 drug candidate in platinum
Benzinga · 07/23 11:22

Industry

Biotechnology & Medical Research
+0.26%
Pharmaceuticals & Medical Research
+1.45%

Hot Stocks

Symbol
Price
%Change

About ARAV

Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.
More

Webull offers kinds of Aravive Inc stock information, including NASDAQ:ARAV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARAV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARAV stock methods without spending real money on the virtual paper trading platform.